Literature DB >> 8439506

Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990.

V Raina1, N K Shukla, G K Rath, N P Gupta, M C Mishra, T K Chaterjee, A K Kripalani.   

Abstract

A retrospective analysis of 108 cases of primary germ cell tumours of testis seen over a 6 year period at Institute Rotary Cancer Hospital of All India Institute of Medical Sciences, New Delhi is presented. There were 45 (42%) cases of seminoma and 63 (48%) of non-seminomatous germ cell tumours (NSGCT). The median age at presentation was 35 and 30 years respectively. Almost half (56) patients presented in advanced stage (stages IIc-IV). Tumours in undescended testis formed an important subgroup (14%). The standard approach of treatment was radiotherapy in stages I & II seminomas and chemotherapy in bulky seminomas and metastatic NSGCT. Chemotherapy protocols used were VAB-6 and PVB. Although a policy of surveillance has been practised for stage I NSGCT, it is debatable whether it is universally suitable for our patients. The results of treatment in low volume disease are comparable to that in the west but the management of bulky disease requires a more aggressive approach. Unfortunately only 74 out of 108 (68.5%) patients were able to complete the treatment prescribed. Most of the defaulters were from the chemotherapy group because of inability to afford the drugs. The probability of survival of those who completed treatment was 0.77 at 4 years. Since testicular tumours are largely curable, a more vigorous policy of detection, follow up and treatment needs to be pursued. Better screening of children with undescended testis will reduce cancer in this group. Failure to provide chemotherapy to all patients is particularly unfortunate for a curable disease like testis cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8439506      PMCID: PMC1968273          DOI: 10.1038/bjc.1993.105

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  5 in total

1.  VAB-6 combination chemotherapy in disseminated cancer of the testis.

Authors:  D Vugrin; H W Herr; W F Whitmore; P C Sogani; R B Golbey
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

2.  Combined management of malignant teratoma of the testis.

Authors:  M J Peckham; T J McElwain; A Barrett; W F Hendry
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

3.  Testicular germ cell tumors. A review of 10 years' experience.

Authors:  R K Grover; V Kaushal; B D Gupta
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

4.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

5.  Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985.

Authors:  J Graham; M Harding; L Mill; D J Kerr; E Rankin; K C Calman; S B Kaye
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

  5 in total
  3 in total

1.  Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.

Authors:  S V Saju; Venkatraman Radhakrishnan; Trivadi S Ganesan; Manikandan Dhanushkodi; Anand Raja; Ganesarajah Selvaluxmy; Tenali Gnana Sagar
Journal:  Med Oncol       Date:  2019-02-06       Impact factor: 3.064

2.  Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting.

Authors:  Anjana Joel; Namrata Mathew; Shalom Sylvester Andugala; Sherin Daniel; Birla Roy Gnanamuthu; Ajoy Oommen John; Josh Thomas Georgy; Raju Titus Chacko; Aparna Irodi; Bijesh Yadav; Subhashini John; Ashish Singh
Journal:  Ecancermedicalscience       Date:  2021-02-11

Review 3.  Germ cell tumours in uncorrected cryptorchid testis at Institute Rotary Cancer Hospital, New Delhi.

Authors:  V Raina; N K Shukla; N P Gupta; S Deo; G K Rath
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.